Array將重獲諾華抗癌藥Binimetinib開發和營銷權

　　本周三，諾華與Array Biopharma公司簽署協議宣布，Array將重新獲得其抗癌藥物Binimetinib的開發和營銷權利。

　　Array重購Binimetinib將有可能促其獲得GSK的抗癌藥Mekinist：今年四月諾華宣布與葛蘭素史克（GSK）進行一項業務重組，GSK的抗癌藥業務被列入其中，一旦明年年初重組完成，諾華將從GSK獲得其近期被核準的MEK抑制劑Mekinist，而Binimetinib也是一種MEK抑制劑，諾華將有必要把Mekinist轉讓給艾瑞。

　　諾華將支付給Array的8500萬美元作為對Binimetinib的全球開發和營銷，根據協議直到諾華與GSK交易完成時結束。諾華也將繼續提供一定的資金和后勤支持Binimetinib正在進行的三個III期研究，這些研究招募患有NRAS突變黑色素瘤、BRAF突變黑色素瘤和低度惡性漿液性卵巢癌的患者。三個III期研究中NRAS突變黑色素瘤的研究結果預計可能在2016年年初完成。

　　隨著Binimetinib的回歸，Array將轉向啟動投入全部資金的治療復發/難治性多發性骨髓瘤的filanesib三期研究，這有可能于2015年上半年開始，接近于諾華交易的完成。

以下為原文：

　　Array Biopharma (ARRY) is regaining full development and marketing rights to its experimental cancer drug binimetinib from Novartis (NVS) , according to an agreement between the two companies announced Wednesday.

　　The re-acquisition of binimetinib by Array was expected after Novartis announced in April a business swap with GlaxoSmithKline (GSK) which included the acquisition of Glaxo's cancer drug business. Once that deal closes early next year, Novartis will own Glaxo's recently approved MEK inhibitor Mekinist. Binimetinib is also a MEK inhibitor, which necessitated Novartis returning the drug to Array.

　　Array will receive $85 million from Novartis to go along with worldwide development and marketing rights to binimetinib, according to term of the new agreement, which will close when the Novartis-Glaxo deal is fully consumated. Novartis will also continue to provide some financial and logistical support to three ongoing, phase III studies of binimetinib. These studies are enrolling patients with NRAS-mutant melanoma, BRAF-mutant melanoma and low-grade serous ovarian cancer.

　　Of the three phase III studies, results from the NRAS-mutant melanoma study are expected first, likely in early 2016.

　　With binimetinib back in house, Array will turn to starting a phase III study its wholly owned asset filanesib in relapsed/refractory multiple myeloma, which could start in the first half of 2015, pending the close of the Novartis agreement. This study will compare filanesib plus Amgen's(AMGN) Kyprolis against Kyprolis and a placebo.

　　Array finished the third quarter with $111 million in cash.